Literature DB >> 2446422

Location of a neutralization determinant in the E protein of yellow fever virus (17D vaccine strain).

M Lobigs1, L Dalgarno, J J Schlesinger, R C Weir.   

Abstract

The location of a major antigenic determinant involved in the neutralization of a flavivirus, yellow fever virus (YF), has been defined in terms of its position in the amino acid sequence of the E protein. Neutralization escape variants of the 17D vaccine strain of YF were selected with two neutralizing monoclonal antibodies. Nucleotide sequencing of the envelope protein genes (E and M) of the variants showed that in each variant there was a single nucleotide change in the E gene leading to a nonconservative amino acid substitution in the E protein at position 71 or 72. The changes are in a region of the E protein which is hydrophilic, rich in cysteine residues, and not conserved between flavivirus subgroups. Since the selecting monoclonal antibodies neutralize attenuated 17D and virulent Asibi strains of YF with equal efficiency (J. J. Schlesinger, M. W. Brandriss, and T. P. Monath, 1983, Virology 125, 8-17), it can be concluded that the neutralization determinant defined for 17D YF is also present in Asibi YF.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2446422     DOI: 10.1016/0042-6822(87)90141-3

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  Identification of envelope protein epitopes that are important in the attenuation process of wild-type yellow fever virus.

Authors:  B K Sil; L M Dunster; T N Ledger; M R Wills; P D Minor; A D Barrett
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  Mutagenesis of the signal sequence of yellow fever virus prM protein: enhancement of signalase cleavage In vitro is lethal for virus production.

Authors:  E Lee; C E Stocks; S M Amberg; C M Rice; M Lobigs
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Use of a lambda gt11 expression library to localize a neutralizing antibody-binding site in glycoprotein E2 of Sindbis virus.

Authors:  K S Wang; J H Strauss
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

4.  Identification of antigenically important domains in the glycoproteins of Sindbis virus by analysis of antibody escape variants.

Authors:  E G Strauss; D S Stec; A L Schmaljohn; J H Strauss
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

5.  A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Jacob J Schlesinger; Carol D Blair; John T Roehrig
Journal:  Antiviral Res       Date:  2012-02-15       Impact factor: 5.970

Review 6.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

7.  Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model.

Authors:  C W Mandl; F Guirakhoo; H Holzmann; F X Heinz; C Kunz
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

8.  Direct sequencing of genomic cDNA fragments amplified by the polymerase chain reaction for molecular epidemiology of dengue-2 viruses.

Authors:  V Deubel; R M Nogueira; M T Drouet; H Zeller; J M Reynes; D Q Ha
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

9.  Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model.

Authors:  Justin G Julander; Brett A Thibodeaux; John D Morrey; John T Roehrig; Carol D Blair
Journal:  Antiviral Res       Date:  2014-01-03       Impact factor: 5.970

10.  A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.

Authors:  Amanda E Calvert; Kandice L Dixon; Joseph Piper; Susan L Bennett; Brett A Thibodeaux; Alan D T Barrett; John T Roehrig; Carol D Blair
Journal:  Antiviral Res       Date:  2016-04-26       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.